Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that
Paul A. Friedman, M.D., President and CEO of Incyte Corporation, has
been appointed to its Board of Directors.
"Sirtris is very pleased to welcome Dr. Friedman to our Board of
Directors. Paul brings with him extensive experience in drug development
and pharmaceutical company management and will be a tremendous asset to
our organization," said Christoph Westphal, M.D., Ph.D., CEO and Vice
Chair of Sirtris Pharmaceuticals, Inc.
“Sirtris’ mission is
to develop new therapeutics for treating Type 2 Diabetes and other
diseases of aging,” said Paul Friedman, M.D.,
President and CEO of Incyte Corporation. “I am
looking forward to joining the Sirtris Board and to actively
contributing to its important mission.”
In 2001, Dr. Friedman became President and Chief Executive Officer of
Incyte Corporation, a Wilmington, Delaware-based drug discovery and
development company focused on developing proprietary small molecule
drugs to treat serious unmet medical needs. Incyte's pipeline includes
multiple compounds in Phase II development for oncology, inflammation,
diabetes and HIV.
Dr. Friedman served as President of Research and Development for the
DuPontMerck Pharmaceutical Company from 1994 to 1998, and from 1998 to
2001, he was the president of DuPont Pharmaceuticals Research
Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991
to 1994, Dr. Friedman served as Senior Vice President at Merck Research
Laboratories. Prior to his work at Merck and DuPont, he was Associate
Professor of Medicine and Pharmacology at Harvard Medical School.
Dr. Friedman is a diplomate of the American Board of Internal Medicine,
a member of the American Society of Pharmacology and Experimental
Therapeutics, a member of the American Society of Clinical Investigation
and a member of the American Society of Biological Chemistry. Dr.
Friedman received his A.B. in Biology from Princeton University and his
M.D. from Harvard Medical School.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. The Company's headquarters
are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators for diseases of aging, such as Type 2
Diabetes and disorders, such as MELAS; the progress and results of
pre-clinical and clinical studies of SIRT1 activators; and the potential
of sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack of
results that would provide a basis for predicting whether any of the
Company's product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results, the
Company's potential inability to initiate and complete pre-clinical
studies and clinical trials for its product candidates, the fact that
none of the Company's product candidates has received regulatory
approvals, the potential inability of the Company to gain market
acceptance of the Company's product candidates, and those other risks
factors that can be found in the Company's filings with the Securities
and Exchange Commission. Actual results may differ materially from those
Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.